Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: JNJ-67864238 in Crohn's Disease
NCT04102111Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- Nov 2021
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of PTG-200 in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Sep 2019; status: terminated.
02
Drugs
PTG-200
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04102111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102111.